Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Jun;32(6):E55-9.
doi: 10.1002/clc.20310.

Quantification of myocardial iron overload by cardiovascular magnetic resonance imaging T2* and review of the literature

Affiliations
Review

Quantification of myocardial iron overload by cardiovascular magnetic resonance imaging T2* and review of the literature

Ashok K Kondur et al. Clin Cardiol. 2009 Jun.

Abstract

Heart failure due to myocardial iron overload remains the leading cause of death in patients with transfusion-dependent anemias. Iron overload-induced cardiomyopathy is reversible if intensive chelation therapy is instituted on time. Thus, early detection of myocardial iron deposition is imperative to prevent overt heart failure. Conventional cardiac monitoring, including physical examination, electrocardiography, echocardiography or serum ferritin levels fail to predict manifest or subclinical myocardial involvement resulting from iron overload. Cardiovascular magnetic resonance imaging T2* (cMRI-T2*, pronounced T2 star) times correlate well with myocardial iron levels. This timely review focuses on the utility of cMRI-T2*, for the preclinical detection of myocardial iron overload and monitoring of myocardial iron content during chelation therapy.

PubMed Disclaimer

References

    1. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, et al.: Cardiovascular T2‐star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22: 2171–2179. - PubMed
    1. Aldouri MA, Wonke B, Hoffbrand AV, Flynn DM, Ward SE, et al.: High incidence of cardiomyopathy in beta‐thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematol 1990; 84: 113–117. - PubMed
    1. Davis BA, Porter JB: Long‐term outcome of continuous 24‐hour deferoxamine infusion via indwelling intravenous catheters in high‐risk beta‐thalassemia. Blood 2000; 95: 1229–1236. - PubMed
    1. Nienhuis AW, Griffith P, Strawczynski H, Henry W, Borer J, et al.: Evaluation of cardiac function in patients with thalassemia major. Ann N Y Acad Sci 1980; 344: 384–396. - PubMed
    1. Buja LM, Roberts WC: Iron in the heart. Etiology and clinical significance. Am J Med 1971; 51: 209–221. - PubMed

MeSH terms